How Much Does TRT Cost? The Monthly Price, the Lab Bill and the First-Year Total

The monthly price is only part of it. The lab schedule sets the rest, and it comes from the Endocrine Society's 2018 clinical practice guideline on testosterone therapy in men with hypogonadism.

Before treatment, the guideline asks for total testosterone measured on two separate mornings, because a single low result is not a diagnosis. After it starts, testosterone and hematocrit are measured at 3 to 6 months, then at 12 months and annually. Hematocrit is checked at baseline too, because testosterone can thicken the blood.

The assumption, stated plainly: twelve billed months of the testosterone program, a baseline comprehensive panel and one follow-up comprehensive panel at the 3-to-6-month check, with nothing else added. Spread across twelve months, that is roughly $191 a month.

The same arithmetic for enclomiphene, with the same two panels, is $1,946. Its monitoring is set by your clinician rather than by the testosterone guideline, so treat that figure as a comparison of prices only.

A confirming morning test. If your first panel shows a low or borderline testosterone, the second morning measurement the guideline requires is another draw before anything is prescribed. If it is a second comprehensive panel, add $199. Getting the test right explains why the timing matters.

The 12-month check landing inside year one. The guideline's 12-month testosterone and hematocrit check falls right at the year's edge. If your clinician draws it in month 12, a third panel brings the year to $2,485.

A result that needs a recheck. A rising hematocrit, a PSA change or a level outside the target range usually means a repeat draw sooner than planned.

Stopping or pausing. Monthly billing means a year you stop in month five is five months of program charges, not twelve. Cancellation terms are shown at enrollment. Stopping testosterone is a clinical decision as well as a billing one; stopping TRT covers why.

The welcome offer. New patients get 10% off the first order through the welcome page. It does not apply to lab panels. Shipping and taxes, where they apply, are shown before you pay.

Often, yes, if you meet the plan's criteria, so someone with good coverage may pay less through insurance than through ACT 2. Testosterone replacement is FDA-approved for diagnosed hypogonadism, and generic testosterone products sit on many drug lists.

What insurers require is fairly consistent. Cigna's published drug coverage policy for oral, topical and nasal testosterone requires prior authorization and, for a new start, all of the following: persistent symptoms of androgen deficiency, two pretreatment testosterone measurements taken in the early morning on two separate days, and both results below the laboratory's normal range, with documentation. Aetna's policy for testosterone cypionate injections asks for at least two confirmed low morning levels before therapy starts. Both track the medical standard: the American Urological Association defines low testosterone by a total testosterone below its guideline cutoff, measured on two separate early mornings, together with symptoms.

Plans also use step therapy. Cigna's policy, on some drug lists, asks a patient to have tried one or two generic topical testosterone products before it covers a branded oral capsule. Medicare drug plans can apply the same tools: prior authorization, step therapy and quantity limits.

ACT 2 does not bill insurance, Medicare or Medicare Advantage for treatments or lab panels. Enclomiphene ODT is compounded, and compounded drugs are not FDA-approved, so it is not a product a pharmacy benefit is built to cover. If you have coverage and meet the criteria, price the insured route first. The pricing and insurance FAQ covers HSA and FSA use; so does the FSA and HSA year-end guide.